STALLERGENES-GREER
18.5.2020 09:07:12 CEST | Business Wire | Press release
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the expansion of the supply of subcutaneous products (SCIT), further broadening its offering to patients and the medical community through a sustained investment in quality and operational excellence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005223/en/
“Stallergenes Greer is committed to the disciplined execution of the company’s strategy and is well advanced on its transformation journey. Our robust fundamentals, investments in quality, and commitment to operational excellence continue to yield results as evidenced by the expansion of SCIT products, the widening of our portfolio and the solidifying of our leadership positions in various markets. We can be proud of our achievements and look ahead with confidence,” declares Michele Antonelli, Chief Executive Officer.
Acceleration of SCIT production
In April 2020, the French Agency for Medicines and Health (ANSM) lifted its injunction, which primarily impacted the production of subcutaneous products for the Europe and International region. SCIT production will fully resume in Antony, France, in the coming weeks, starting with skin prick tests (Alyostal® pricks) for diagnosis, and Alustal® for the treatment of patients with allergies. SCIT production in the US, where Stallergenes Greer continues to lead the market, has remained fully operational and was not part of the injunction.
With sustained investments in its global manufacturing capabilities, Stallergenes Greer operates state-of-the-art manufacturing and quality systems that meet the highest product quality standards.
Stallergenes Greer intends to further provide injectable forms with the resumption of Phostal®.
SCIT products meet the needs of patients whose profile and lifestyle require an alternative access to treatment and delivery mode, longer intervals between treatment, or monitoring of adherence by their physician.
Further broadening the allergen immunotherapy treatment portfolio
Stallergenes Greer remains determined to offer an extensive portfolio of treatment solutions tailored to each patient profile and to each market, including injectable therapies, sublingual therapies such as drops and tablets, venoms and diagnostics. From diagnosis to treatment, Stallergenes Greer’s portfolio is designed to ensure the consistency of its products in terms of active ingredients and high-quality standards. It allows physicians to choose the administration method which is best suited to each patient’s needs and lifestyle.
In 2019 alone, the company added 15 new Staloral® allergen references to its sublingual portfolio and will launch another 10 references in 2020.
Stallergenes Greer, also continued to enhance its tablet offering which already includes Oralair® for the treatment of grass pollen allergies and Actair® for the treatment of house dust mite allergies, which is distributed in selected countries of the Asia-Pacific region.
The company recently submitted a European marketing application authorisation for its house dust mite allergy immunotherapy tablet. The tablet is also under New Drug Submission review by Health Canada.
Stallergenes Greer is delivering on the disciplined execution of its strategy of providing people with allergies a broad range of personalised treatment options, which will make it both a company with a complete portfolio and a valued partner for patients and the medical community.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Midas Atlantic Partners, in Partnership With the Najafi Companies, Has Entered Into a Put Option Agreement With Sylvamo Relating to the Potential Acquisition of Its European Operations6.11.2026 12:04:00 CET | Press release
Sylvamo’s European operations include its uncoated freesheet paper mills in Saillat (France) and Nymölla (Sweden), as well as its forestry and supporting business operations across EuropeRevenues of approximately EUR 630 million for the fiscal year ended December 2025Transaction expected to close in the first quarter of 2027 once the required consultation processes are completed and regulatory approvals are obtained Midas Atlantic Partners (“Midas Atlantic”), in partnership with The Najafi Companies, has signed a put option agreement with Sylvamo Corporation (“Sylvamo”) relating to the potential acquisition of its European operations (the “Business”). The transaction comprises Sylvamo’s uncoated freesheet paper mills in Saillat and Nymölla, as well as its forestry and supporting business operations across Europe. Closing is expected in the first quarter of 2027, once the required consultation processes are completed and regulatory approvals are obtained. The Business is a leading Europ
Suzano Reports 36% Increase in Third Quarter Net Revenue Following Consolidation of Arbex6.11.2026 00:23:00 CET | Press release
Suzano (B3: SUZB3 / NYSE: SUZ) , the world’s largest pulp producer, announces its results for the third quarter of 2026 (3Q26), which for the first time include Arbex, the joint venture between Suzano and Kimberly-Clark established in July this year. Driven primarily by the consolidation of Arbex’s contribution, Suzano reported net revenue of BRL16.5 billion, an increase of 36% on the same period last year and a new quarterly record in the company’s 102-year history. Adjusted EBITDA totaled R$5.7 billion in 3Q26, up 9% on the same basis of comparison. Operating cash generation reached R$3.8 billion, an increase of 12%. Net income totaled R$2.1 billion. As announced following the completion of the transaction with Kimberly-Clark, Suzano holds a 51% equity interest in Arbex and will therefore fully consolidate the joint venture’s financial statements from this quarter onwards.1 “This quarter marks the beginning of a new phase for Suzano. With Arbex, we are now a broader business, both ge
Andersen Consulting styrker sine transformationskompetencer med Bakia Consulting5.11.2026 23:12:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for forretningstransformation gennem en samarbejdsaftale med Bakia Consulting, et firma, der har specialiseret sig i transformation af økonomifunktionen. Bakia Consulting har hovedkontor i Paris og kapacitet i Singapore og Hongkong og har hjulpet store virksomheder og finansielle institutioner med at gentænke deres økonomifunktioner, herunder driftsmodeller, organisationsstrukturer, processer og digitale systemer. Bakia Consulting kombinerer projektledelse og forandringsledelse og arbejder tæt sammen med kunderne om at udvikle løsninger og fastholde forandringer. Virksomheden rådgiver også om modeller for økonomisk og ikke-økonomisk styring, procesoptimering og digitale værktøjer. "Økonomifunktioner forventes at levere bedre indsigt, arbejde mere effektivt og tilpasse sig skiftende forretningsbehov – ofte samtidig," udtalte Romain Dubuisson, partner hos Bakia Consulting. "Vi arbejder tæt sammen med vores kunder om at udvikle løsninger,
iQmetrix Unveils Built-In Intelligence for Every Role in Telecom Commerce at Its 2026 Telecom Industry Address5.11.2026 22:39:00 CET | Press release
An all-new AI inventory agent, iQ Hub and iQ Pay for Back Office bring intelligence to every role. iQmetrix, the global provider of Intelligent Commerce Operating Systems for telecom, last week shared highlights from its 2026 Telecom Industry Address and Product Announcements, held virtually on Oct. 28 in two sessions, one for North American audiences and one for European audiences. The address was built around one theme: intelligence. Telecom commerce is moving from systems that record the business to systems that act on it, and the announcements put that intelligence in the hands of every role, from the sales associate at the counter, to the finance manager in the back office, to the corporate view leading the channel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105003162/en/ "Right now telecom providers are competing in a race to the bottom on price that no one wins. The way out is intelligence. Not AI bo
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.11.2026 22:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to nine newly hired non-executive employees. The equity awards were granted on November 2, 2026, and consisted of options to purchase an aggregate of 59,275 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 28,200 shares. These options have an exercise price per share equal to $8.41, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom